Innovent

News

ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data

Takeda and Innovent's CLDN18.2-targeting ADC, arcotatug tavatecan, will be filed in Japan on the back of positive survival data in gastric cancer.

News

Spero snaps up Innovent immunology drug in strategic pivot

Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.

Oncology

ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...

Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.

News

Innovent in line for $10.5bn in Pfizer cancer alliance

Pfizer has signed a strategic-level alliance with Innovent, worth $10.5bn and spanning 12 cancer assets, in another sign of China's rising R&D status.

News